Literature DB >> 21989842

Cerebral infarction in adults with bacterial meningitis.

Ewout S Schut1, Marjolein J Lucas, Matthijs C Brouwer, Mervyn D I Vergouwen, Arie van der Ende, Diederik van de Beek.   

Abstract

BACKGROUND: To evaluate clinical features and prognostic factors of cerebral infarctions in adults with community-acquired bacterial meningitis.
METHOD: An observational cross-sectional study, including 696 patients of whom 174 had cerebral infarction, from a prospective nationwide cohort of community-acquired bacterial meningitis (period, 1998-2002), confirmed by culture of cerebral spinal fluid (CSF) in patients aged over 16 years. Two investigators independently determined the presence of infarction. RESULT: Cerebral infarction occurred in 174 episodes (25%), with a high inter-rater agreement for determining the presence of cerebral infarction (kappa 0.95). Cerebral infarctions occurred in 128 of 352 patients (36%) with pneumococcal meningitis, in 22 of 257 (9%) with meningococcal meningitis and in 24 of 87 patients (28%) with meningitis caused by other bacteria. Patients with infarctions were older (P < 0.001) and often presented with predisposing conditions, such as otitis and/or sinusitis (P = 0.001) or an immunocompromised state (P = 0.003) compared to those without infarction. Patients with infarctions presented with lower scores on the Glasgow Coma Scale (P < 0.001), lower CSF white cell counts (P = 0.001), and higher serum erythrocyte sedimentation rate (ESR) (P < 0.001). Unfavorable outcome occurred in 108 (62%) patients with infarctions. In a multivariate analysis, infarction was related with unfavorable outcome (odds ratio 3.37; 95% confidence interval 2.19-5.21; P < 0.001). We identified lower CSF white cell counts and high ESR to be independent risk factors for cerebral infarction.
CONCLUSION: Cerebral infarction is a common and severe complication in adults with community-acquired bacterial meningitis. Preventing cerebral infarctions will be important in reducing the high morbidity and mortality rate in adults with community-acquired bacterial meningitis.

Entities:  

Mesh:

Year:  2012        PMID: 21989842     DOI: 10.1007/s12028-011-9634-4

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.532


  30 in total

Review 1.  BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. 1. GENERAL CLINICAL FEATURES, SPECIAL PROBLEMS AND UNUSUAL MENINGEAL REACTIONS MIMICKING BACTERIAL MENINGITIS.

Authors:  M N SWARTZ; P R DODGE
Journal:  N Engl J Med       Date:  1965-04-22       Impact factor: 91.245

Review 2.  Bidirectional relation between inflammation and coagulation.

Authors:  Marcel Levi; Tom van der Poll; Harry R Büller
Journal:  Circulation       Date:  2004-06-08       Impact factor: 29.690

Review 3.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Cerebrovascular complications of bacterial meningitis in adults.

Authors:  H W Pfister; G D Borasio; U Dirnagl; M Bauer; K M Einhäupl
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

5.  Procoagulant and fibrinolytic activity in cerebrospinal fluid from adults with bacterial meningitis.

Authors:  Martijn Weisfelt; Rogier M Determann; Jan de Gans; Arie van der Ende; Marcel Levi; Diederik van de Beek; Marcus J Schultz
Journal:  J Infect       Date:  2007-01-04       Impact factor: 6.072

6.  Diffuse cerebral intravascular coagulation and cerebral infarction in pneumococcal meningitis.

Authors:  Mervyn D I Vergouwen; Ewout S Schut; Dirk Troost; Diederik van de Beek
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

7.  Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series.

Authors:  Martijn Weisfelt; Diederik van de Beek; Lodewijk Spanjaard; Johannes B Reitsma; Jan de Gans
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

8.  Clinical features and prognostic factors in adults with bacterial meningitis.

Authors:  Diederik van de Beek; Jan de Gans; Lodewijk Spanjaard; Martijn Weisfelt; Johannes B Reitsma; Marinus Vermeulen
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

9.  Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis.

Authors:  M C Brouwer; S G B Heckenberg; J de Gans; L Spanjaard; J B Reitsma; D van de Beek
Journal:  Neurology       Date:  2010-09-29       Impact factor: 9.910

Review 10.  Pneumococcal meningitis in adults: new approaches to management and prevention.

Authors:  Martijn Weisfelt; Jan de Gans; Tom van der Poll; Diederik van de Beek
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

View more
  24 in total

1.  Virulence Traits of a Serogroup C Meningococcus and Isogenic cssA Mutant, Defective in Surface-Exposed Sialic Acid, in a Murine Model of Meningitis.

Authors:  Roberta Colicchio; Chiara Pagliuca; Susanna Ricci; Elena Scaglione; Denis Grandgirard; Ilias Masouris; Fabrizio Farina; Caterina Pagliarulo; Giuseppe Mantova; Laura Paragliola; Stephen L Leib; Uwe Koedel; Gianni Pozzi; Pietro Alifano; Paola Salvatore
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

2.  Bedside evaluation of cerebral energy metabolism in severe community-acquired bacterial meningitis.

Authors:  Frantz R Poulsen; Mette Schulz; Anne Jacobsen; Åse B Andersen; Lykke Larsen; Wilhelm Schalén; Troels H Nielsen; Carl-Henrik Nordström
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

3.  Delayed cerebral thrombosis in bacterial meningitis: a prospective cohort study.

Authors:  Marjolein J Lucas; Matthijs C Brouwer; Diederik van de Beek
Journal:  Intensive Care Med       Date:  2012-12-18       Impact factor: 17.440

4.  Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy?

Authors:  Barry B Mook-Kanamori; Daan Fritz; Matthijs C Brouwer; Arie van der Ende; Diederik van de Beek
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 5.  Individuality, phenotypic differentiation, dormancy and 'persistence' in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology.

Authors:  Douglas Kell; Marnie Potgieter; Etheresia Pretorius
Journal:  F1000Res       Date:  2015-07-01

6.  Outcome in patients with bacterial meningitis presenting with a minimal Glasgow Coma Scale score.

Authors:  Marjolein J Lucas; Matthijs C Brouwer; Arie van der Ende; Diederik van de Beek
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-05-15

7.  Rampant spread of infection in an afebrile immune-competent patient presenting with young-onset ischaemic stroke.

Authors:  Umang Arora; Animesh Ray; Surabhi Vyas; Naval Kishore Vikram
Journal:  BMJ Case Rep       Date:  2020-08-25

8.  Pneumococcal meningitis: clinical-pathological correlations (MeninGene-Path).

Authors:  Joo-Yeon Engelen-Lee; Matthijs C Brouwer; Eleonora Aronica; Diederik van de Beek
Journal:  Acta Neuropathol Commun       Date:  2016-03-22       Impact factor: 7.801

9.  V-akt murine thymoma viral oncogene homolog 3 (AKT3) contributes to poor disease outcome in humans and mice with pneumococcal meningitis.

Authors:  Mercedes Valls Serón; Bart Ferwerda; JooYeon Engelen-Lee; Madelijn Geldhoff; Valery Jaspers; Aeilko H Zwinderman; Michael W Tanck; Frank Baas; Arie van der Ende; Matthijs C Brouwer; Diederik van de Beek
Journal:  Acta Neuropathol Commun       Date:  2016-05-18       Impact factor: 7.801

10.  Variation of 46 Innate Immune Genes Evaluated for their Contribution in Pneumococcal Meningitis Susceptibility and Outcome.

Authors:  Bart Ferwerda; Mercedes Valls Serón; Aldo Jongejan; Aeilko H Zwinderman; Madelijn Geldhoff; Arie van der Ende; Frank Baas; Matthijs C Brouwer; Diederik van de Beek
Journal:  EBioMedicine       Date:  2016-07-12       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.